Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Hemostemix Closes CDN$280,594 Private Placement

By The Northwire Desk — AI Analysis Nov 18, 2025 · 17:08 HEM · 0.085 Hemostemix Inc.
HEM · Price

Executive Summary

  • Hemostemix Inc. received conditional TSX Venture Exchange approval for a non‑brokered private placement of 2,244,752 common shares at CDN $0.125 per share, amounting to CDN $280,594.
  • Proceeds are earmarked for general working capital, ongoing operational expenses, and business development activities.
  • All issued securities are subject to a four‑month hold period under Canadian securities laws.

Key Details

  • Offering Size: CDN $280,594 total gross proceeds.
  • Shares Issued: 2,244,752 common shares.
  • Price per Share: CDN $0.125.
  • Conditional Approval: TSX Venture Exchange conditionally approved the placement; final issuance pending final TSXV approval.
  • Investor Status: Investor is arm’s‑length and not a related party at time of disclosure (per TSXV Policy 4.1).
  • Use of Proceeds: General working capital, support for continuing operational expenses, and business development activities.
  • Holding Period: Four‑month hold period from closing date per Canadian securities regulations; additional restrictions may apply in other jurisdictions.
  • No Undisclosed Material Changes: Company confirms no material fact or change has been omitted from prior disclosures.

Notable Quotes

(None provided in the release)

Read the original news release →

More from Hemostemix Inc.

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory Dec 31, 2025 · 18:13

Hemostemix closes $480,000 financing

Financings